

ASX Release

**FULL YEAR RESULTS FY2023**

**Highlights:**

- Finalising and launching a new medical sales channel product Ready, Attention, Go!
- Creating a new education channel product AttentionTime!
- Red Dot Design Award for Ready,Attention,Go!
- Strategic review results in strategic partnership expansion with Genius Childcare
- \$2.3m net loss and \$2.0m net operating cash outflows. Closing cash of \$3.0m at 30 June 2023

Melbourne, 31st August 2023: TALi Digital Limited (TALi) (ASX: TD1), a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour, today released its Financial Report for the year ended 30 June 2023.

**Financial update**

TALi recorded a loss of \$2.3m for the year ending 30 June 2023 (30 June 2022: \$6.9m). TALi's net operating cash outflows for the year was \$2.0m (30 June 2022: \$4.3m) and reported closing cash of \$3.0m at 30 June 2023 (30 June 2022: \$1.8m) with an estimated Research and Development Tax Incentive refund of \$0.7m for FY23 expected to be received in Q2 FY24.

**Outlook**

TALi is well positioned to implement the outcomes of the strategic review which include driving sales and marketing efforts of its products through the Genius partnership whilst remains focused on maximising value for its shareholders by seeking aligned opportunities to grow and expand the business to deliver that value.

— ENDS —

**Release authorised by:**

The Board of TALi Digital Limited

**CONTACT**

**Corporate & Investors**

Mark Simari

Chair

TALi Digital 1300 082 013

investors@talidigital.com

### About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at [talidigital.com](https://talidigital.com).